Upregulation of a specific protein may be an indicator of radiation resistance in patients with resected non-small cell lung cancer who received radiotherapy.
A recent study examined whether a history of Epstein-Barr virus positivity or immunosuppression affects outcomes in patients with a type of B-cell lymphoma.
The US FDA has granted approval to an adjuvant therapy for HER2-positive breast cancer at high risk of recurrence.
The US Food and Drug Administration approved an adjuvant treatment for patients with completely resected melanoma.
A new drug developed by Merck & Co and Pfizer Inc won U.S. approval on Wednesday to treat type II diabetes, the Food and Drug Administration said, adding another competitor to a growing class of treatments.
A recent study compared the effects of laser-assisted resection with pulmonary metastasectomy in patients with extrathoracic sarcoma.
A single-agent therapy is an effective chemotherapy-free option for patients with marginal zone lymphoma previously exposed to conventional monotherapy.
Adding a specific class of inhibitors to multiple myeloma treatment may not improve survival outcomes, but it does reduce overall pain and vertebral fractures.
Cancer treatments from Pfizer Inc and Exelixis Inc on Tuesday won approval from the US Food and Drug Administration for expanded use in previously untreated patients.
A clinical pathway for patients with prostate cancer patients improved the implementation of evidence-based strategies for the management of androgen deprivation therapy-induced side effects.